Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma (Q24244152)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

1 reference

title

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

F M Ducharme

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

T J Lasserson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

18 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

CD003137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17054161%20AND%20SRC:MED&resulttype=core&format=json

Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Pharmacokinetic profile of zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

New combination therapies for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Formoterol protects against platelet-activating factor-induced effects in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Traditional and patient-centred outcomes with three classes of asthma medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Treatment of bronchial asthma using a new adjustable combination treatment plan: Asthma Control Plan (ATACO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Efficacy of antileukotriene agents in asthma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Fixed combination of inhalant steroids and long-acting beta(2) agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

What is new since the last (1999) Canadian Asthma Consensus Guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

New insights into the understanding of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Mucosal inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Leukotriene receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Adult Asthma Consensus Guidelines update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Antagonism of long-acting beta2-adrenoceptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

ABC of Asthma. Treatment of chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Clinical trials: are these your patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Active cigarette smoking and asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Clinical evidence with montelukast in the management of chronic childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

The prospects for long-term intervention in asthma with antileukotrienes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Randomized comparison of strategies for reducing treatment in mild persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

[Cost-effectiveness of an intervention based on the Global INitiative for Asthma (GINA) recommendations using a computerized clinical decision support system: a physicians randomized trial]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Guidelines for the evaluation of impairment/disability in patients with asthma. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

The role of leukotriene modifiers in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Expression and release of interleukin-8 by human airway smooth muscle cells: inhibition by Th-2 cytokines and corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Inhaled corticosteroid doses in asthma: an evidence-based approach.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB3

7 January 2021